1. PI3K/Akt/mTOR
  2. mTOR

Deforolimus (Synonyms: AP23573; MK-8669; Ridaforolimus; AP 23573; MK 8669; AP-23573; MK8669)

Cat. No.: HY-50908
Handling Instructions

Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin.

For research use only. We do not sell to patients.
Deforolimus Chemical Structure

Deforolimus Chemical Structure

CAS No. : 572924-54-0

Size Price Stock Quantity
10 mg $77 In-stock
50 mg $296 Backordered
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products

Featured Recommendations

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

Description

Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. IC50 value: 0.2 nM [1] Target: mTOR in vitro: Treatment of HT-1080 cells with Deforolimus induces a dose-dependent inhibition of phosphorylation of both S6 and 4E-BP1, with IC50 of 0.2 nM and 5.6 nM, respectively, and leads to a decrease in cell size, an increase in the proportion of cells in the G1 phase of the cell cycle, and inhibition of glucose uptake. Deforolimus displays significant antiproliferative activity a broad panel of cell lines with EC50 of 0.2-2.3 nM. Deforolimus potently and selectively inhibits VEGF production in a dose-dependent manner [1]. Deforolimus treatment significantly induces growth suppression in human NSCLC cell lines with IC30 values of 2.45-8.83 nM, with the exception of H157 with IC30 of >20 nM. Deforolimus treatment (2.8-5.9 nM) significantly dephosphorylates p70S6KThr389 in A549, H1703 and H157 cells, except H1666 that may express a resistant variant of mTORC1, and causes increased phosphorylation of pAKTser473 and pAKTThr308 in A549 and H1703 cells. Deforolimus in combination with the MEK inhibitors, CI-1040 or PD0325901 exhibits dose-dependent synergism in lung cancer cell lines, which is associated with the suppression of proliferation rather than enhancement of cell death, involving the inhibition of ribosomal biogenesis by 40% within 24 hours and a decreased polysome/monosome ratio [2]. in vivo: Administration of Deforolimus exerts significant antitumor effects in mice bearing PC-3 (prostate), HCT-116 (colon), MCF7 (breast), PANC-1 (pancreas) or A549 (lung) xenografts in a dose-dependent manner, and inhibits mTOR signaling in in SK-LMS-1 xenograft model associated with inhibition of tumor growth [1].

Clinical Trial
Sponsor Condition Start Date Phase
Merck & Co Inc Bone tumor 2007-10-31 Phase 3
Merck & Co Inc Sarcoma 2007-10-31 Phase 3
Merck & Co Inc Metastatic breast cancer 2012-07-31 Phase 2
Rajavithi Hospital Cholangiocarcinoma 2012-01-31 Phase 2
Memorial Sloan-Kettering Cancer Center Renal cell carcinoma 2011-07-31 Phase 2
Merck & Co Inc Metastatic breast cancer 2010-09-30 Phase 2
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.0099 mL 5.0494 mL 10.0989 mL
5 mM 0.2020 mL 1.0099 mL 2.0198 mL
10 mM 0.1010 mL 0.5049 mL 1.0099 mL
M.Wt

990.21

Formula

C₅₃H₈₄NO₁₄P

CAS No.

572924-54-0

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 44 mg/mL

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Deforolimus
Cat. No.:
HY-50908
Quantity: